-
New target CD99 CAR-T for T-ALL releases research data
Time of Update: 2021-11-16
Recent popular reports from Yimaike ★The first cancer immunotherapy for adjuvant treatment of NSCLC was approved, reducing the risk of early lung cancer recurrence by 34% ★Wu Zhiwei/Liu Yalan team jointly developed inhaled new nanoantibodies to effectively inhibit new coronavirus infections October 26, 2021/Doctor EMedClub News/--Recently, Professor Zhang Tongcun of Wuhan Polytech Biosciences published a titled "CAR T cells targeting CD99 as" in the international authoritative journal "Journal of Hematology & Oncology" (IF 17.
-
Knowing Lymphology·Phase 3 Pathology Expert Talk: How to clarify the idea of differential diagnosis of lymphoma?
Time of Update: 2021-11-16
In order to further enhance the pathologist’s ability in the clinical differential diagnosis of common tissue diseases and lymphoma, and reduce the occurrence of missed lymphoma diagnosis, the "Knowl
-
The relationship between several gene mutations and prognosis in acute myeloid leukemia (part 1)
Time of Update: 2021-11-15
Previous studies have shown that the MLLT3-KMT2A fusion gene is related to the occurrence of monocyte phenotype of AML, and it has the characteristics of rapid disease progression, high recurrence rate and short survival period [10,11] .
-
Cancer Communications Meng Guoyu/Huang Jinyan/Chen Zhu/Hu Weiguo made new breakthroughs in the pathogenesis of B-cell acute lymphoblastic leukemia
Time of Update: 2021-11-15
This research is a new breakthrough in the collaboration of Meng Guoyu/Huang Jinyan/Chen Zhu/Hu Weiguo to promote clinical transformation by expounding the pathogenesis of DUX4/IGH type leukemia .
-
Ibrutinib combined with Venecla is an effective oral non-chemotherapeutic regimen for initial treatment of CLL patients
Time of Update: 2021-11-15
Research methods The newly diagnosed CLL patients included in this study are all indicated for treatment and meet at least one of the following characteristics: del(17p), TP53, del(11q), IGHV without mutation or age ≥65 years .
-
STTT Nanjing Medical University Li Jianyong and Fan Lei found that Sintilimab can potentially treat relapsed/refractory extranodal NK/T cell lymphoma
Time of Update: 2021-11-15
This study (ORIENT-4) aims to evaluate Sintilimab (Sintilimab, a humanized anti-PD-1 antibody) in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) In the efficacy and safety .
-
Gathering in the Cloud, Peak Dialogue-Professor Usmani talks about optimizing treatment for relapsed MM
Time of Update: 2021-11-15
Usmani pointed out that the treatment of RRMM needs to consider the patient, disease and previous treatment factors to choose a plan: patients who are not refractory to first-line bortezomib can still choose treatment based on proteasome inhibitors after the first relapse .
-
Express Innovative Mechanism of Action, Novartis Leukemia Therapy Receives FDA Approval Today
Time of Update: 2021-11-15
▎The content team editor of WuXi AppTec today, Novartis announced that the US FDA has approved Scemblix (asciminib) for the treatment of two different indications of chronic myeloid leukemia (CML) .
-
Experience Sharing of the Latest Approved PK Software from Other Stones (5): British Experience
Time of Update: 2021-11-15
PK-guided individualized preventive treatment can reduce the risk of bleeding in patients with hemophilia, reduce the frequency and dose of coagulation factor infusion, increase factor trough concentration, and reduce medical costs, so that patients are expected to live an ideal life .
-
PNH Famous Doctors Lecture Session 7 Professor Guangsheng He: Treatment of PNH-Pregnancy
Time of Update: 2021-11-15
After using C5 monoclonal antibody in PNH pregnant patients, hemolysis can be controlled, anemia will be improved, hemoglobin level will be normal, the placenta is not ischemic, not hypoxic, the development is intact, and the fetus is also intact .
-
FDA updates asciminib to treat Philadelphia chromosome-positive patients with chronic myeloid leukemia
Time of Update: 2021-11-15
The recommended dose of asciminib for CP Ph+ CML patients who have previously received ≥2 TKI treatments is 80 mg, once a day, orally at about the same time a day, or 40 mg, twice a day, with an interval of about 12 hours .
-
A 2-year-old girl has repeated severe anemia, "who" stole her blood?
Time of Update: 2021-11-15
Due to severe anemia (58 g/L of hemoglobin), the local doctor gave red blood cell infusion and iron treatment, and his condition gradually improved, his hemoglobin rose to 90 g/L, and he was discharged .
-
Kymriah, the world's first CAR-T product, receives priority review for its new indication
Time of Update: 2021-11-15
S. Food and Drug Administration (FDA) has accepted its CAR-T product Kymriah (tisagenlecleucel) supplementary biologics license application (sBLA) for the treatment of relapsed or refractory (r /r) Adult patients with follicular lymphoma (FL) .
-
Ma Guanghui/Wei Wei/Martin/Li Yuhua developed a biomimetic delivery vehicle loaded with arsenic, which significantly inhibits a variety of leukemias
Time of Update: 2021-11-15
The State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, based on ferritin particles (Fn) and the approved drug arsenic trioxide (ATO) in the body, proposed a new biomimetic delivery strategy and cooperated with Peking University and Zhujiang Hospital.
-
New transplantation strategies and post-transplant treatment options for ALL patients from an international perspective
Time of Update: 2021-11-15
The accessibility of donors is generally improved, which meets the needs of patients who need allo-HSCT, but the pursuit of the best transplant strategy and maintenance treatment options after transplantation to maintain long-term disease-free survival (DFS) with minimal therapeutic toxicity still needs to be explored .
-
Express Innovative PI3Kδ Inhibitor obtained FDA priority review qualification, Cinda Biotech owns rights and interests in Greater China
Time of Update: 2021-11-15
Retrieved November 1, 2021, from https:// [2] Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas.
-
Real-world study: How should elderly patients with ITP use TPO receptor agonists?
Time of Update: 2021-11-15
Based on this, some researchers analyzed the response of ITP patients ≥60 years of age to TRA treatment, as well as the conversion of different TRA types, the risk of thrombosis/bleeding, and the patient's sustained response to treatment discontinuation (SROT) .
-
The relationship between several gene mutations and prognosis in acute myeloid leukemia (part 2)
Time of Update: 2021-11-15
RUNX1 mutations in acute myeloid leukemia:results from a comprehensive genetic and clinical analysis from the AML study group.
RUNX1 mutations in acute myeloid leukemia:results from a comprehensive genetic and clinical analysis from the AML study group.
-
How much do you know about renal anemia in children?
Time of Update: 2021-11-15
Figure 2 A single-center study of anemia in children with CKD (picture from Professor Li Qiu's PPT) Anemia increases the risk of cardiovascular disease and death in CKD patients .
-
How effective is Pembro-Rd consolidation therapy after ASCT for high-risk multiple myeloma?
Time of Update: 2021-11-15
Based on this, the researchers conducted an open-label, phase II single-arm clinical trial to evaluate the PD-1 inhibitor pembrolizumab combined with lenalidomide and dexamethasone (Pembro-Rd) after ASCT in MM patients Consolidate the efficacy and safety of treatment .
